PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
Pharmabiz1d
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
Business Insider3d
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology (AIM-MASH) tool can be used in metabolic dysfunction associated ...
heise online3d
EU Medicines Agency assesses first AI diagnosis as "scientifically valid"
The tool, called AIM-NASH (Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology) from Boston-based Path AI, supports pathologists in analyzing liver biopsy scans to ...
pharmaphorum2d
EMA panel endorses AI for MASH clinical trials
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
The Manila Times6d
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...